WO2006075094A3 - Derives de la purine, compositions les contenant et leurs utilisation contre le cancer - Google Patents

Derives de la purine, compositions les contenant et leurs utilisation contre le cancer Download PDF

Info

Publication number
WO2006075094A3
WO2006075094A3 PCT/FR2006/000065 FR2006000065W WO2006075094A3 WO 2006075094 A3 WO2006075094 A3 WO 2006075094A3 FR 2006000065 W FR2006000065 W FR 2006000065W WO 2006075094 A3 WO2006075094 A3 WO 2006075094A3
Authority
WO
WIPO (PCT)
Prior art keywords
same
compositions containing
purine derivatives
against cancer
derivatives compositions
Prior art date
Application number
PCT/FR2006/000065
Other languages
English (en)
Other versions
WO2006075094A2 (fr
Inventor
Chantal Carrez
Florence Fassy
Patrick Mailliet
Fabienne Thompson
Original Assignee
Aventis Pharma Sa
Chantal Carrez
Florence Fassy
Patrick Mailliet
Fabienne Thompson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa, Chantal Carrez, Florence Fassy, Patrick Mailliet, Fabienne Thompson filed Critical Aventis Pharma Sa
Priority to EP06709072A priority Critical patent/EP1841769A2/fr
Priority to JP2007550815A priority patent/JP2008526930A/ja
Publication of WO2006075094A2 publication Critical patent/WO2006075094A2/fr
Publication of WO2006075094A3 publication Critical patent/WO2006075094A3/fr
Priority to US11/773,572 priority patent/US20080119467A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/40Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Dérivés de la purine de formule (IA1) ou (IB1):, compositions les contenant et utilisation comme médicaments, en particulier en oncologie, dans laquelle Y et Z représentent N ou CH ; X représente un atome d'halogène ; dans (IA), A représente N ou CH et dans (IB), A représente O, S, NH, CH2 ou CHR ; B représente O, S, NR’, CH2 ou CHR’ ; R représente H ou alkyle ; R’ représente H, alkyle, alkényle, alkynyle ; (CH2)n-aryle ou hétéroaryle ;-CH(aryle)2; C(Z)-aryle ou hétéroaryle ; éventuellement substitués ; n= 0, 1 , 2 ; Z représente O, S ou NR'.
PCT/FR2006/000065 2005-01-13 2006-01-11 Derives de la purine, compositions les contenant et leurs utilisation contre le cancer WO2006075094A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP06709072A EP1841769A2 (fr) 2005-01-13 2006-01-11 Derives de la purine, compositions les contenant et leurs utilisation contre le cancer
JP2007550815A JP2008526930A (ja) 2005-01-13 2006-01-11 プリン誘導体、プリン誘導体を含有する組成物およびこの使用
US11/773,572 US20080119467A1 (en) 2005-01-13 2007-07-05 Purine Derivatives, Compositions Containing Them and Use Thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0500349A FR2880626B1 (fr) 2005-01-13 2005-01-13 Derives de la purine, compositions les contenant et utilisation
FR0500349 2005-01-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/773,572 Continuation US20080119467A1 (en) 2005-01-13 2007-07-05 Purine Derivatives, Compositions Containing Them and Use Thereof

Publications (2)

Publication Number Publication Date
WO2006075094A2 WO2006075094A2 (fr) 2006-07-20
WO2006075094A3 true WO2006075094A3 (fr) 2006-12-07

Family

ID=34954725

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2006/000065 WO2006075094A2 (fr) 2005-01-13 2006-01-11 Derives de la purine, compositions les contenant et leurs utilisation contre le cancer

Country Status (6)

Country Link
US (1) US20080119467A1 (fr)
EP (1) EP1841769A2 (fr)
JP (1) JP2008526930A (fr)
AR (1) AR052454A1 (fr)
FR (1) FR2880626B1 (fr)
WO (1) WO2006075094A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
DK3421471T3 (da) * 2006-04-25 2021-06-14 Astex Therapeutics Ltd Purin- og deazapurinderivater som farmaceutiske forbindelser
CA2660114A1 (fr) * 2006-08-09 2008-02-14 Merck Frosst Canada Ltd. Derives d'azacycloalcane en tant qu'inhibiteurs de la stearoyl-coenzyme a delta-9 desaturase
WO2008075007A1 (fr) * 2006-12-21 2008-06-26 Cancer Research Technology Limited Composé bicyclohétéroarylés substitué par morpholino et leur utilisation en tant qu'agents anti-cancer
US20080233127A1 (en) * 2007-03-21 2008-09-25 Wyeth Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
SI2201012T1 (sl) 2007-10-11 2014-10-30 Astrazeneca Ab Derivati pirolo(2,3-D)pirimidina kot inhibitorji proteina kinaze B
ES2665277T3 (es) * 2009-03-13 2018-04-25 Katholieke Universiteit Leuven K.U. Leuven R&D Análogos de purina y su uso como agentes inmunosupresores
DK2694056T3 (da) 2011-04-01 2020-01-02 Astrazeneca Ab Terapeutisk behandling
MY175800A (en) 2011-11-30 2020-07-09 Astrazeneca Ab Combination treatment of cancer
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
WO2013182612A1 (fr) * 2012-06-07 2013-12-12 Bayer Pharma Aktiengesellschaft Inhibiteurs de transport du glucose
CA2983042C (fr) * 2015-04-21 2020-01-07 Lijuan Chen Derives de purinyl-n-hydroxylpyrimidine-formamide, leur procede de preparation et leur utilisation
CZ2016608A3 (cs) * 2015-10-26 2017-01-18 Ústav experimentální botaniky AV ČR, v. v. i. 2,6-disubstituované puriny pro použití jako léčiva, a farmaceutické přípravky
CZ306987B6 (cs) * 2015-10-26 2017-11-01 Ústav experimentální botaniky AV ČR, v. v. i. 2,6-disubstituované puriny pro použití jako léčiva a farmaceutické přípravky je obsahující

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020078A1 (fr) * 1992-04-03 1993-10-14 The Upjohn Company Amines bicycliques-heterocycliques efficaces pharmaceutiquement
WO1998005235A1 (fr) * 1996-08-01 1998-02-12 A.W. Faber-Castell Unternehmensverwaltung Gmbh & Co. Crayon a mine tendre
WO1999002162A1 (fr) * 1997-07-12 1999-01-21 Cancer Research Campaign Technology Limited Derives de purine inhibant la kinase dependant de la cycline
WO1999065909A1 (fr) * 1998-06-19 1999-12-23 Pfizer Products Inc. COMPOSES DE PYRROLO[2,3-d]PYRIMIDINE
WO2000044750A1 (fr) * 1999-02-01 2000-08-03 Cv Therapeutics, Inc. INHIBITEURS PURIQUES DES KINASES 2 ET IλB-α DEPENDANTES DES CYCLINES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5929046A (en) * 1994-06-08 1999-07-27 Cancer Research Campaign Technology Limited Pyrimidine and purine derivatives and their use in treating tumour cells
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
US7842693B2 (en) * 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
EP1682150B1 (fr) * 2003-11-10 2012-12-26 The Scripps Research Institute Compositions et procedes pour induire la dedifferenciation cellulaire

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020078A1 (fr) * 1992-04-03 1993-10-14 The Upjohn Company Amines bicycliques-heterocycliques efficaces pharmaceutiquement
WO1998005235A1 (fr) * 1996-08-01 1998-02-12 A.W. Faber-Castell Unternehmensverwaltung Gmbh & Co. Crayon a mine tendre
WO1999002162A1 (fr) * 1997-07-12 1999-01-21 Cancer Research Campaign Technology Limited Derives de purine inhibant la kinase dependant de la cycline
WO1999065909A1 (fr) * 1998-06-19 1999-12-23 Pfizer Products Inc. COMPOSES DE PYRROLO[2,3-d]PYRIMIDINE
WO2000044750A1 (fr) * 1999-02-01 2000-08-03 Cv Therapeutics, Inc. INHIBITEURS PURIQUES DES KINASES 2 ET IλB-α DEPENDANTES DES CYCLINES

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOHNSTON, THOMAS P. ET AL: "Synthesis of potential anticancer agents. XVI. S-Substituted derivatives of 6-mercaptopurine", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY , 80, 6265-71 CODEN: JACSAT; ISSN: 0002-7863, 1958, XP009052623 *
PANAGOPOULOS, KIM ET AL: "Synthesis of potent anticancer agents. I. 6-(1-Pyrrolidyl)purines, 6-(1-piperidyl)purines, and their nucleosides", ARZNEIMITTEL-FORSCHUNG , 15(3), 204-7 CODEN: ARZNAD; ISSN: 0004-4172, 1965, XP009052694 *
THOMPSON, ROBERT D. ET AL: "N6,9-Disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor", JOURNAL OF MEDICINAL CHEMISTRY , 34(9), 2877-82 CODEN: JMCMAR; ISSN: 0022-2623, 1991, XP002048672 *

Also Published As

Publication number Publication date
US20080119467A1 (en) 2008-05-22
FR2880626A1 (fr) 2006-07-14
JP2008526930A (ja) 2008-07-24
WO2006075094A2 (fr) 2006-07-20
EP1841769A2 (fr) 2007-10-10
AR052454A1 (es) 2007-03-21
FR2880626B1 (fr) 2008-04-18

Similar Documents

Publication Publication Date Title
WO2006075094A3 (fr) Derives de la purine, compositions les contenant et leurs utilisation contre le cancer
SE0302811D0 (sv) Novel compounds
TW200800999A (en) Novel compounds
SE0202539D0 (sv) Compounds
WO2007048064A3 (fr) Aminopyrimidines en tant que modulateurs de caseine kinase ii (ck2)
WO2010003475A8 (fr) Nouveaux dérivés de pyrrolidine utilisés comme inhibiteurs de la metap-2
UA103873C2 (ru) Гетероарильные производные мочевины как ингибиторы р38 и их применение
TW200616995A (en) Novel compounds
WO2005021544A3 (fr) Inhibiteurs d'un ensemble d'imidazopyridine c n3 substitue
GEP20115231B (en) 2-amino-7,8-dihydro-6h-pyrido [4,3-d] pyrimidin-5-ones
IL184872A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
IL185063A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
IL188494A0 (en) Novel 2,4-dianlinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as ikk inhibitors
SE0301700D0 (sv) Novel compounds
UA84712C2 (en) N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
TW200745084A (en) Novel compounds
TW200635917A (en) Novel compounds
WO2006116733A3 (fr) Inhibiteurs des proteines kinases
MX2009011578A (es) 6-fenilpirimidinonas como moduladores de pim.
NO20076333L (no) Anvendelse av thiazolderivater og analoge i behandling av kreft
TW200635916A (en) Compounds
TW200639156A (en) New compounds
WO2006125555A3 (fr) Chinazolinones
WO2007120333A3 (fr) Inhibiteurs de kinase tétracycliques
IL173810A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007550815

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006709072

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2006709072

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11773572

Country of ref document: US